Antifungal therapy for chronic pulmonary aspergillosis

Lancet Infect Dis. 2022 Jul;22(7):924-926. doi: 10.1016/S1473-3099(22)00126-8. Epub 2022 Apr 13.

Authors

Adilia Warris¹, Darius Armstrong-James²

Affiliations

¹ Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, EX4 4QD, UK. Electronic address: a.warris@exeter.ac.uk.
² Medical Research Council Centre for Molecular Microbiology and Infection, Department of Infectious Diseases, Imperial College London, London, UK.

PMID: 35429464
DOI: 10.1016/S1473-3099(22)00126-8

No abstract available

Publication types

Comment

MeSH terms

Antifungal Agents / therapeutic use
Aspergillosis* / drug therapy
Chronic Disease
Humans
Pulmonary Aspergillosis* / drug therapy

Substances

Antifungal Agents

Grants and funding

MR/V033417/1/MRC_/Medical Research Council/United Kingdom